• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transbound Emerg Dis . Comparison of diagnostic performances of different serological tests for SARS-CoV-2 antibody detection in cats and dogs

tetano

Editor, Senior Moderator
Transbound Emerg Dis


. 2022 Oct 1.
doi: 10.1111/tbed.14716. Online ahead of print.
Comparison of diagnostic performances of different serological tests for SARS-CoV-2 antibody detection in cats and dogs


Gabriele Ratti[SUP] 1 [/SUP], Davide Lelli[SUP] 2 [/SUP], Ana Moreno[SUP] 2 [/SUP], Angelica Stranieri[SUP] 1 [/SUP], Tiziana Trogu[SUP] 2 [/SUP], Alessia Giordano[SUP] 1 [/SUP], Andrea Grassi[SUP] 3 [/SUP], Camilla Luzzago[SUP] 1 [/SUP], Nicola Decaro[SUP] 4 [/SUP], Saverio Paltrinieri[SUP] 1 [/SUP], Stefania Lauzi[SUP] 1 [/SUP]



Affiliations

Abstract

Serosurveillance among animals, including pets, plays an important role in the current coronavirus disease 2019 (COVID-19) pandemic, because severe acute respiratory coronavirus 2 (SARS-CoV-2) infections in animal populations could result in the establishment of new virus reservoirs. Serological assays that offer the required sensitivity and specificity are essential. In this study we evaluated the diagnostic performance of three different commercially available immunoassays for the detection of SARS-CoV-2 antibodies in pets, namely two ELISA tests for the detection of antibodies against SARS-CoV-2 nucleocapsid [ID Screen SARS CoV-2 double antigen multispecies (Double antigen) and ID Screen® SARS-CoV-2-N IgG indirect ELISA (Indirect)] and one test for the detection of neutralizing antibodies against SARS-CoV-2 receptor-binding-domain [surrogate virus neutralization test (sVNT)]. The obtained results were compared with those of conventional virus neutralization test (VNT), which was regarded as reference method. A total of 191 serum samples were analyzed. Thirteen (6.8%) samples showed VNT positive results. The overall sensitivity was higher for sVNT (100%) compared to nucleocapsid-based ELISA assays (23% for Double antigen and 60% for Indirect). The specificity was 100% for Indirect ELISA and sVNT, when a higher cut-off (>30%) was used compared to the one previously defined by the manufacturer (>20%), whereas the other test showed lower value (99%). The sVNT test showed the highest accuracy and agreement with VNT, with a perfect agreement when the higher cut-off was applied. The agreement between each nucleocapsid-based ELISA test and VNT was 96% for Indirect and 94% for Double antigen. Our findings showed that some commercially available serological tests may lead to a high rate of false negative results, highlighting the importance of assays validation for the detection of SARS-CoV-2 antibodies in domestic animals. This article is protected by copyright. All rights reserved.

Keywords: Serosurveillance; cats; diagnostic tests accuracy; dogs; immunological assay; severe acute respiratory coronavirus 2.
 
Back
Top Bottom